Stifel analyst Paul Matteis reiterated a Hold rating and $68.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments